Positron Emission Mammography May Reduce Unnecessary Breast Biopsies

A common physician complaint regarding the use of breast MRI is its tendency to identify suspicious lesions, requiring biopsies on lesions that ultimately are found to be benign.

This finding is a welcomed outcome for women and physicians looking for ways to reduce the patient trauma associated with biopsies and for payers looking to reduce the costs associated with unnecessary procedures. The 388 woman study showed that PEM not only demonstrated a six percent improvement in specificity at comparably high sensitivity, but that PEM also had 31 fewer unnecessary biopsies, and 26% higher PPV than breast magnetic resonance imaging (MRI0) scans. These results are also particularly significant for those women who cannot tolerate an MRI exam and require an alternate imaging tool.

"The results of this study mean that not only do physicians have an additional, powerful tool to help treat breast cancer but that PEM is a legitimate and better alternative for the 16% of women who cannot tolerate MR due to claustrophobia, metallic implants, body habitus, or gadolinium reaction,” said Wendie Berg, M.D., Ph.D., a radiologist from American Radiology Services (ARS), Johns Hopkins Medical Institutions (Lutherville, MD, USA) and lead investigator for the trial. Dr. Berg recently published an article in the January 2010 issue in the journal Radiology examining the reasons why high-risk women who were recommended for a MR breast-screening test refused to take the exam.

PEM scanners are high-resolution breast positron emission tomography (PET) systems that can reveal the location as well as the metabolic phase of a lesion. This information is critical in determining whether a lesion is malignant and influences the course of treatment. Other imaging systems, such as mammography and ultrasound, show only the location, not the metabolic phase. PEM scanners, which are about the size of an ultrasound system, are manufactured by Naviscan, Inc. (San Diego, CA, USA) and have been commercially available since 2007.

The U.S. National Institutes of Health (NIH); Bethesda, MD, USA)-sponsored multisite study examined women with newly-diagnosed breast cancer. Patients were accrued from six leading clinical centers across the United States: ARS Johns Hopkins Green Spring (MD, USA), Boca Raton Community Hospital (FL, USA), Scripps Clinic-Scripps Green Hospital (San Diego, CA, USA), University of North Carolina (Chapel Hill, USA), University of Southern California Norris Cancer Center (Los Angeles, USA), and Anne Arundel Medical Center (Annapolis, MD, USA).

Related Links:
Johns Hopkins Medical Institutions
Naviscan